Latest News - IQVIA
Top Corporates Hub
IQVIA
IQVIA Gears Up to Post Q3 Earnings: Here's What Investors Should Know
22.10.2026 12:58
IQV is poised for y/y revenue and earnings growth in Q3, driven by stronger clinical research demand, solid bookings, AI adoption and operational efficiencies.
IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy?
20.10.2026 13:00
IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IQVIA: R&D Bookings Are Reaccelerating, But The Valuation Now Requires Execution
20.10.2026 11:21
IQVIA (IQV) earns a Buy rating on strong Q2 results and R&D bookings recovery. See growth drivers, AI upside, key risks, and $285â$305 target.
IQVIA HOLDINGS INC (NYSE:IQV) Sets Up for Breakout With Strong Technical Ratings
20.10.2026 09:00
IQVIA (IQV) earns 9/10 technical and setup ratings, consolidating near 52-week highs. See breakout entry, support, resistance, and key risks.
1 Large-Cap Stock to Research Further and 2 We Avoid
19.10.2026 10:16
Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.
3 Low-Volatility Stocks with Questionable Fundamentals
16.10.2026 13:15
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
IQVIA: A $34.2 Billion Backlog Does Not Guarantee Faster Earnings Growth
16.10.2026 08:06
IQVIA Holdings (IQV) reported robust Q2 2026 results, with 8.7% revenue growth and a 19% increase in Research & Development Solutions bookings.
VEEV Expands IQVIA Partnership With Clinical Operations Software Suite
14.10.2026 13:44
Veeva expands its IQVIA partnership with clinical operations software, boosting its market reach and growth prospects through wider adoption and integrated workflows.
Stifel Maintains Buy on IQVIA Holdings, Raises Price Target to $303
14.10.2026 07:44
Stifel analyst Shlomo Rosenbaum maintains IQVIA Holdings (NYSE:IQV) with a Buy and raises the price target from $276 to $303.
Could You Have Seen The Run In Tempus AI Stock Coming?
09.10.2026 14:19
Tempus AI (TEM) stock returned 56.9% in the six months from April 9 to October 8, 2026. Partway through that timeline, on July 30, the company finally reported a quarterly profit following years of losses. Yet the stock's run began more than three months before that earnings report. Market moves of this scale always look obvious in hindsight. Had Tempus signaled that positive net income—or breakeven on an adjusted basis—was finally within reach.
UBS Reinstates Buy on IQVIA Holdings, Announces $345 Price Target
30.09.2026 08:19
UBS analyst Kevin Caliendo reinstates IQVIA Holdings (NYSE:IQV) with a Buy and announces $345 price target.
RBC Capital Maintains Outperform on IQVIA Holdings, Raises Price Target to $319
29.09.2026 08:33
RBC Capital analyst Ryan Halsted maintains IQVIA Holdings (NYSE:IQV) with a Outperform and raises the price target from $247 to $319.
RBC Capital Maintains Outperform on IQVIA Holdings, Raises Price Target to $319
29.09.2026 08:33
RBC Capital analyst Ryan Halsted maintains IQVIA Holdings (NYSE:IQV) with a Outperform and raises the price target from $247 to $319.
Can Doximity Keep Shrinking Its Share Count Through Its AI Investment Year?
24.09.2026 13:25
Doximity (DOCS), which calls itself the leading digital platform for U.S. medical professionals, has seen its stock fall steeply over the past year. Even after a rise over the past three months, the shares sit about 65% below their 52-week high. Management continued its repurchase program, allocating approximately $401 million over the latest twelve months. The test is whether it can keep that up through what it calls its AI investment year.
Novo Nordisk: Capital Markets Day Reveals Its Next Growth Engine
24.09.2026 09:39
Novo Nordisk A/Sâs 2030 pipeline targets, Wegovy pill growth and Q2 sales show major upside. Click for this NVO stock update.
IQVIA (IQV): Buy, Sell, or Hold Post Q2 Earnings?
08.09.2026 14:31
The past six months have been a windfall for IQVIA’s shareholders. The company’s stock price has jumped 50%, hitting $267.77 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
VEEV Raises FY27 Outlook as Vault CRM and AI Momentum Accelerate Fast
03.09.2026 18:10
Veeva raises its fiscal 2027 outlook as Vault CRM adoption, R&D growth and Falcon AI momentum support expanding revenue and profitability.
Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report?
03.09.2026 15:30
TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
This Healthcare Services Stock Has 37% Upside
13.08.2026 12:01
Well-known pharmaceutical companies such as Merck and Pfizer typically manage this complex process in house. Medpace Holdings which targets oncology, metabolic, cardiology, central nervous system, and anti-infective therapies, raised its 2026 revenue guidance on July’s second-quarter conference call to a midpoint of $2.85 billion, corresponding to a year-over-year increase of 13%. Three months later, Medpace is in the pink: On the heels of second-quarter earnings, the stock is up 14%.
How Investors Are Reacting To IQVIA Holdings (IQV) Cardiac Gene Therapy Push And Higher 2026 Revenue Outlook
09.08.2026 15:11
In late July and early August 2026, IQVIA Holdings and Medera announced a collaboration pairing IQVIA’s global clinical and commercialization infrastructure with Medera’s Sardocor and Novoheart cardiac gene therapy and human-based drug discovery platforms, alongside IQVIA’s second-quarter results, raised full-year 2026 revenue guidance to between US$17.28 billion and US$17.48 billion, and continued share repurchases. The partnership’s focus on AAV-based cardiac gene therapies and Novoheart’s...